SES vs. GSK
SES (SES AI Corp) and GSK (GlaxoSmithKline plc) are both stocks. SES operates in Auto Parts (Consumer Cyclical), while GSK operates in Drug Manufacturers - General (Healthcare). Over the past 5 years, SES returned -36.15%/yr vs 5.34%/yr for GSK. At a 0.05 correlation, their price movements are largely independent.
Performance
SES vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SES achieves a -40.56% return, which is significantly lower than GSK's 9.89% return.
SES
- 1D
- 0.00%
- 1M
- -5.31%
- YTD
- -40.56%
- 6M
- -47.55%
- 1Y
- 11.83%
- 3Y*
- -20.00%
- 5Y*
- -36.15%
- 10Y*
- —
GSK
- 1D
- 0.34%
- 1M
- 6.78%
- YTD
- 9.89%
- 6M
- 10.40%
- 1Y
- 34.50%
- 3Y*
- 19.84%
- 5Y*
- 5.34%
- 10Y*
- 5.35%
SES vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
SES SES AI Corp | -40.56% | -17.81% | 19.67% | -41.90% | -68.34% | -5.24% |
GSK GlaxoSmithKline plc | 9.89% | 51.23% | -5.14% | 9.71% | -33.41% | 36.34% |
Correlation
The correlation between SES and GSK is -0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.04 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.01 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.05 |
Correlation (All Time) Calculated using the full available price history since Mar 1, 2021 | 0.05 |
Fundamentals
SES:
$356.14M
GSK:
$108.04B
SES:
-$0.22
GSK:
£2.85
SES:
16.19
GSK:
2.47
SES:
1.75
GSK:
3.42
SES:
$21.92M
GSK:
£32.78B
SES:
$7.97M
GSK:
£23.87B
SES:
-$68.11M
GSK:
£11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SES vs. GSK — Risk / Return Rank
SES
GSK
SES vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SES AI Corp (SES) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SES | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.02 | ||
| Sortino ratioReturn per unit of downside risk | -0.75 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.20 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | 0.10 | 1.58 | -1.48 |
| Martin ratioReturn relative to average drawdown | 0.17 | 3.92 | -3.75 |
Loading charts...
Drawdowns
SES vs. GSK - Drawdown Comparison
The maximum SES drawdown since its inception was -97.58%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for SES and GSK.
Loading charts...
Drawdown Indicators
| SES | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.58% | -55.70% | -41.88% |
Max Drawdown (1Y)Largest decline over 1 year | -74.08% | -18.63% | -55.45% |
Max Drawdown (3Y)Largest decline over 3 years | -91.41% | -28.46% | -62.95% |
Max Drawdown (5Y)Largest decline over 5 years | -97.58% | -50.10% | -47.48% |
Max Drawdown (10Y)Largest decline over 10 years | — | -50.10% | — |
Current DrawdownCurrent decline from peak | -90.39% | -11.92% | -78.47% |
Average DrawdownAverage peak-to-trough decline | -65.76% | -18.87% | -46.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 45.30% | 8.28% | +37.02% |
Volatility
SES vs. GSK - Volatility Comparison
SES AI Corp (SES) has a higher volatility of 27.05% compared to GlaxoSmithKline plc (GSK) at 6.81%. This indicates that SES's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SES | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 27.05% | 6.81% | +20.24% |
Volatility (6M)Calculated over the trailing 6-month period | 76.68% | 18.49% | +58.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 106.91% | 27.06% | +79.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 114.53% | 25.08% | +89.45% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.41% | 22.89% | +88.52% |
Dividends
SES vs. GSK - Dividend Comparison
SES has not paid dividends to shareholders, while GSK's dividend yield for the trailing twelve months is around 3.26%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.26% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
SES SES AI Corp | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
SES vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between SES AI Corp and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SES and GSK have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SES has higher volatility (27.05%) compared to GSK (6.81%). In terms of maximum drawdown, SES dropped -97.58% vs GSK's -55.70%.
GSK currently has the higher Sharpe Ratio (1.09 vs 0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SES and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer